{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"35"},{"groupId":"OG004","value":"60"},{"groupId":"OG005","value":"120"},{"groupId":"OG006","value":"33"}],"units":"Participants"}],"description":"Response that was confirmed on 2 consecutive evaluations\n\n* Complete Response(CR): Complete disappearance of M-protein from serum and urine on immunofixation, normalization of Free Light Chain (FLC) ratio and \\<5% plasma cells in bone marrow.\n* Very Good Partial Response(VGPR): \\>=90% reduction in serum M-component; Urine M-Component \\<100mg per 24hours; \\<=5% plasma cells in bone marrow.\n* Partial Response(PR): \\>=50% reduction in serum M-component and/or Urine M-Component \\>=90% reduction or \\<200mg per 24hours; or \\>=50% decrease in difference between involved and uninvolved FLC levels.","groups":[{"description":"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG000","title":"Relapsed Myeloma (<4 Prior Regimens): Low Dose"},{"description":"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG001","title":"Lenalidomide Refractory Myeloma: Low Dose"},{"description":"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG002","title":"Bortezomib/Lenalidomide Refractory/Relapsed Myeloma: Low Dose"},{"description":"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG003","title":"Bortezomib/Lenalidomide Relapsed/Refractory Myeloma: High Dose"},{"description":"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG004","title":"Relapsed Myeloma (< 4 Prior Regimens): High Dose"},{"description":"Pomalidomide: 4 mg orally once daily, days 1-21 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG005","title":"Relapsed/Refractory Myeloma: High Dose"},{"description":"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG006","title":"Relapsed Amyloidosis: Low Dose"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Duration of study (up to 3 years)","title":"The Number of Confirmed Hematologic Responses (Complete, Partial, or Very Good Partial Response)","type":"PRIMARY","unitOfMeasure":"participants"}